Breast carcinoma expressing predominant neuroendocrine differentiation but lacking specific cyto-architectural features of low grade or high grade neuroendocrine carcinoma
Diagnostic Criteria
At least 50% of cells are neuroendocrine marker positive
We require either synaptophysin or chromogranin
We do not consider neuron specific enolase to be sufficiently specific for this diagnosis
Any conventional breast carcinoma pattern excluding those of:
Small numbers reported but there is no clear clinical difference from conventional carcinoma
Richard L Kempson MD
Robert V Rouse MD
Department of Pathology
Stanford University School of Medicine
Stanford CA 94305-5342
Original posting:: November 15, 2006
Supplemental studies
Immunohistology
Diagnosis requires at least 50% of cells to be neuroendocrine marker positive
We require chromogranin or synaptophysin
We do not consider neuron specific enolase to be sufficiently specific for this diagnosis
Argyrophil stains have ben used
Electron microscopy has been used
GCDFP15 may be positive
Demonstration of myoepithelial cells can confirm the in situ nature of a process while their absence supports invasion
We prefer to use both p63 and calponin on problematic cases
A variety of markers have been used for myoepithelial cells:
Marker
Sensitivity
Specificity
Calponin
Excellent
Very good
p63
Excellent
Excellent
Smooth muscle myosin heavy chain
Good
Excellent
CD10 (CALLA)
Good
Good
High molecular weight cytokeratin
Very good
Poor
Maspin
Good
Poor
S100
Good
Very poor
Actin
Good
Very poor
E-cadherin appears to be a sensitive marker of ductal differentiation vs lobular differentiation; its utility in borderline lesions is currently uncertain
Immunologic markers useful for identification of breast carcinoma
GCDFP15 (BRST2)
Estrogen Receptor
Progesterone Receptor
PAX8
Infiltrating ductal carcinoma
60-70%
75%
50-60%
0%
Infiltrating lobular carcinoma
60-70%
>95%
80%
0%
Lung adenocarcinoma
0-1%
<5%
<5%
0%
Ovarian adenocarcinoma
1-5%
50-100%
40-90%
90-100%
Endometrioid adenocarcinoma
negative
70%
70%
GI adenocarcinoma
negative
<5%
1-10%
0%
Pancreatic adenocarcinoma
negative
negative
0-5%
0%
Cholangiocarcinoma
negative
negative
30%
Thyroid carcinoma
negative
20%
30%
100%
Sweat gland and salivary gland neoplasms may also be positive for GCDFP15, ER and PR
Prostatic adenocarcinoma may be positive for GCDFP15
We are not aware of a series of breast neuroendocrine carcinomas tested for CK7/20
Prognostic/Therapeutic Markers
Estrogen receptor (ER) and progesterone receptor (PR) are important markers for directing therapy and determining prognosis
Current consensus is that any level of positivity should be reported as positive
Her2neu status can be determined by either immunohistology or by FISH
The other technique can be used for borderline case
Genetic analysis
Her2neu status can be determined by either immunohistology or by FISH
The other technique can be used for borderline cases
Differential Diagnosis
Metastatic neuroendocrine carcinoma must be ruled out clinically
Neuroendocrine Carcinomas: Low Grade, High Grade or NOS
Very rare carcinomas have been reported that demonstrate features similar to pulmonary large cell neuroendocrine carcinomas
Clinical
Studies using thresholds of both <50% and >50% cellular reactivity for neuroendocrine markers have found no independent clinical significance in carcinomas with conventional patterns
Prognosis appears to be driven by grade in such cases
Very rare carcinomas have been reported that demonstrate features similar to pulmonary large cell neuroendocrine carcinomas
Bloom-Scarff-Richardson grading scheme is most widely used
Total score and each of the three components should be reported
Based on invasive area only
Tubule formation
Score
>75% tubules
1
10-75% tubules
2
<10% tubules
3
Nuclear pleomorphism (most anaplastic area)
Score
Small, regular, uniform nuclei, uniform chromatin
1
Moderate varibility in size and shape, vesicular, with visible nucleoli
2
Marked variation, vesicular, often with multiple nucleoli
3
Mitotic figure count per 10 40x fields (depends on area of field, see key below)
Score
0.096 mm2
0.12 mm2
0.16 mm2
0.27 mm2
0.31 mm2
0-3
0-4
0-5
0-9
0-11
1
4-7
5-8
6-10
10-19
12-22
2
>7
>8
>10
>19
>22
3
Olympus BX50, BX40 or BH2 or AO or Nikon with 15x eyepiece: 0.096 mm2
AO with 10x eyepiece: 0.12 mm2
Nikon or Olympus with 10x eyepiece: 0.16 mm2
Leitz Ortholux: 0.27 mm2
Leitz Diaplan: 0.31 mm2
Mitotic count figures based on original data presented for Leitz Ortholux by Elston and Ellis 1991, with modifications based on pubished and measured areas of view
Evaluate regions of most active growth, usually in cellular areas at periphery
We employ strict criteria for identification of mitotic figures
Sum of above three components
Overall grade
3-5 points
Grade I (well differentiated)
6-7 points
Grade II (moderately differentiated)
8-9 points
Grade III (poorly differentiated)
Staging
TNM staging is the most widely used scheme for breast carcinomas but is not universally employed
Critical staging criteria for regional lymph nodes
Isolated tumor cell clusters
Usually identified by immunohistochemistry
Term also applies if cells identified by close examination of H&E stain
No cluster may be greater than 0.2 mm
Multiple such clusters may be present in the same or other nodes
Micrometastasis
Greater than 0.2 mm, none greater than 2.0 mm
Metastasis
At least one carcinoma focus over 2.0 mm
If one node qualifies as >2.0 mm, count all other nodes even with smaller foci as involved
Critical numbers of involved nodes: 1-3, 4-9 and 10 and over
Note extranodal extension
Report
Excisions: the following are important elements that must be addressed in the report for infiltrative breast carcinomas
Grade
Total score and individual components
Size of neoplasm
Give 3 dimensions or greatest dimension
Critical cutoffs occur at 0.5 cm and at 2 cm
Margins of resection
Measure and report the actual distance of both invasive and in situ carcinoma
Angiolymphatic invasion
Indicate if confined to tumor mass, outside tumor mass or in dermis
(Extensive DCIS is not currently felt to be a significant predictor of behavior)
Results of special studies performed for diagnosis
Results of prognostic special studies performed
ER, PR, Proliferation marker, Her2neu
If studies were performed on a prior specimen, refer to that report and give results
Needle or core biopsies
Provisional grade may be given but may defer to excision for definitive grade
Presence of absence of angiolymphatic invasion
Results of special studies performed for diagnosis
Results of prognostic special studies if performed
ER, PR, Proliferation marker, Her2neu
State if studies are deferred for a later excision specimen
Sapino A, Bussolati G. Is detection of endocrine cells in breast adenocarcinoma of diagnostic and clinical significance? Histopathology. 2002 Mar;40(3):211-4.
Sapino A, Papotti M, Righi L, Cassoni P, Chiusa L, Bussolati G. Clinical significance of low grade neuroendocrine carcinoma of the breast. Ann Oncol. 2001;12 Suppl 2:S115-7.
Makretsov N, Gilks CB, Coldman AJ, Hayes M, Huntsman D. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol. 2003 Oct;34(10):1001-8.
Miremadi A, Pinder SE, Lee AH, Bell JA, Paish EC, Wencyk P, Elston CW, Nicholson RI, Blamey RW, Robertson JF, Ellis IO. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology. 2002 Mar;40(3):215-22. (All cases had <50% of neuroendocrine cells)
Tse GM, Ma TK, Chu WC, Lam WW, Poon CS, Chan WC. Neuroendocrine differentiation in pure type mammary mucinous carcinoma is associated with favorable histologic and immunohistochemical parameters. Mod Pathol. 2004 May;17(5):568-72.